Table 3.

Summary of biological effects of MICA-129 genotypes and their relation to expected and observed clinical outcomes after HSCT

MICA-129 genotype	NKG2D signaling	NKG2D cell surface expression over time	HSCT outcomes	Clinical outcomes expected in view of biological function	Clinical outcomes observed
Met/Met	strong	reduced	aGVHD	↑a or ↓	↑ occurrenceb ↓ fatalc
			cGVHD	↓	↓d
			relapse	↑	↑d
			overall survival	variable	↑c
Met/Val	intermediate	reduced	aGVHD	→ or ↓	↓ occurrenceb ↓ fatalc
			cGVHD	↓
			relapse	↑
			overall survival	variable	↑c
Val/Val	weak	preserved	aGVHD	↓ or ↑	↓ occurrenceb ↑ fatalc
			cGVHD	↑	↑d
			relapse	↓	↓d
			overall survival	variable	↓c

^a↑ increased, → unchanged, ↓ decreased.

^bAttributable to the group receiving a T-cell-depleting treatment with ATG in our study.

^cAttributable to the group not treated with ATG in our study.

^dData from Boukouaci et al (2009).